Reardon et al. revealed that the combination therapy targeting CTLA-4 and PD-1 cured 70% of glioma mice, higher than the cure rate of PD-1 inhibitor alone, and induced tumor-specific memory effect to prevent recurrence [32]. Here, RPL17 is linked to neoplasm.